190 related articles for article (PubMed ID: 37960147)
1. Propolis Has an Anticancer Effect on Early Stage Colorectal Cancer by Affecting Epithelial Differentiation and Gut Immunity in the Tumor Microenvironment.
Shen MH; Liu CY; Chang KW; Lai CL; Chang SC; Huang CJ
Nutrients; 2023 Oct; 15(21):. PubMed ID: 37960147
[TBL] [Abstract][Full Text] [Related]
2. Increased number of forkhead box P3+ tumor-infiltrating lymphocytes correlates with high preoperative albumin level and better survival in patients with stage II or III colorectal cancer.
Wang DL; Liu YY; Gu YL; Qin Y; Ji HF; Wu LH; Qi N; Su D; Huang SH; Zhang YQ
Tumour Biol; 2015 Jul; 36(7):5407-14. PubMed ID: 25697896
[TBL] [Abstract][Full Text] [Related]
3. Tumor-infiltrating lymphocyte subsets and tertiary lymphoid structures in pulmonary metastases from colorectal cancer.
Schweiger T; Berghoff AS; Glogner C; Glueck O; Rajky O; Traxler D; Birner P; Preusser M; Klepetko W; Hoetzenecker K
Clin Exp Metastasis; 2016 Oct; 33(7):727-39. PubMed ID: 27449756
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the local immune status between the primary and metastatic tumor in colorectal cancer: a retrospective study.
Shibutani M; Maeda K; Nagahara H; Fukuoka T; Matsutani S; Kashiwagi S; Tanaka H; Hirakawa K; Ohira M
BMC Cancer; 2018 Apr; 18(1):371. PubMed ID: 29614981
[TBL] [Abstract][Full Text] [Related]
5. Intravascular emboli relates to immunosuppressive tumor microenvironment and predicts prognosis in stage III colorectal cancer.
Song X; Xie D; Tan F; Zhou Y; Li Y; Zhou Z; Pei Q; Pei H
Aging (Albany NY); 2021 Aug; 13(16):20609-20628. PubMed ID: 34438367
[TBL] [Abstract][Full Text] [Related]
6. Mismatch Repair Status of Gastric Cancer and Its Association with the Local and Systemic Immune Response.
Shin SJ; Kim SY; Choi YY; Son T; Cheong JH; Hyung WJ; Noh SH; Park CG; Kim HI
Oncologist; 2019 Sep; 24(9):e835-e844. PubMed ID: 30894409
[TBL] [Abstract][Full Text] [Related]
7. Differential gene expression of tumor-infiltrating CD4
Sasidharan Nair V; Saleh R; Taha RZ; Toor SM; Murshed K; Ahmed AA; Kurer MA; Abu Nada M; Al Ejeh F; Elkord E
Oncoimmunology; 2020 Sep; 9(1):1825178. PubMed ID: 33101776
[TBL] [Abstract][Full Text] [Related]
8. Blockade of IDO-Kynurenine-AhR Axis Ameliorated Colitis-Associated Colon Cancer via Inhibiting Immune Tolerance.
Zhang X; Liu X; Zhou W; Du Q; Yang M; Ding Y; Hu R
Cell Mol Gastroenterol Hepatol; 2021; 12(4):1179-1199. PubMed ID: 34087454
[TBL] [Abstract][Full Text] [Related]
9. Differential gene expression of tumor-infiltrating CD8
Saleh R; Sasidharan Nair V; Toor SM; Taha RZ; Murshed K; Al-Dhaheri M; Khawar M; Petkar MA; Abu Nada M; Al-Ejeh F; Elkord E
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32948653
[TBL] [Abstract][Full Text] [Related]
10. FOXP3+ Tregs: heterogeneous phenotypes and conflicting impacts on survival outcomes in patients with colorectal cancer.
Zhuo C; Xu Y; Ying M; Li Q; Huang L; Li D; Cai S; Li B
Immunol Res; 2015 Mar; 61(3):338-47. PubMed ID: 25608795
[TBL] [Abstract][Full Text] [Related]
11. Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer.
Teng F; Meng X; Kong L; Mu D; Zhu H; Liu S; Zhang J; Yu J
Transl Res; 2015 Dec; 166(6):721-732.e1. PubMed ID: 26209749
[TBL] [Abstract][Full Text] [Related]
12. Intratumoural-infiltrating CD4 + and FOXP3 + T cells as strong positive predictive markers for the prognosis of resectable colorectal cancer.
Kuwahara T; Hazama S; Suzuki N; Yoshida S; Tomochika S; Nakagami Y; Matsui H; Shindo Y; Kanekiyo S; Tokumitsu Y; Iida M; Tsunedomi R; Takeda S; Yoshino S; Okayama N; Suehiro Y; Yamasaki T; Fujita T; Kawakami Y; Ueno T; Nagano H
Br J Cancer; 2019 Oct; 121(8):659-665. PubMed ID: 31488881
[TBL] [Abstract][Full Text] [Related]
13. Combined Low Densities of FoxP3
Cavalleri T; Bianchi P; Basso G; Celesti G; Grizzi F; Bossi P; Greco L; Pitrone C; Valtorta E; Mauri G; Truini M; Dall'Olio FG; Brandi G; Sartore-Bianchi A; Ricciardiello L; Torri V; Rimassa L; Siena S; Mantovani A; Malesci A; Laghi L;
Cancer Immunol Res; 2019 May; 7(5):751-758. PubMed ID: 30804005
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral infiltrating lymphocytes correlate with improved survival in colorectal cancer patients: Independent of oncogenetic features.
Nazemalhosseini-Mojarad E; Mohammadpour S; Torshizi Esafahani A; Gharib E; Larki P; Moradi A; Amin Porhoseingholi M; Asadzade Aghdaei H; Kuppen PJK; Zali MR
J Cell Physiol; 2019 Apr; 234(4):4768-4777. PubMed ID: 30370522
[TBL] [Abstract][Full Text] [Related]
15. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer.
Peng QH; Wang CH; Chen HM; Zhang RX; Pan ZZ; Lu ZH; Wang GY; Yue X; Huang W; Liu RY
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579737
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoints in Circulating and Tumor-Infiltrating CD4
Toor SM; Murshed K; Al-Dhaheri M; Khawar M; Abu Nada M; Elkord E
Front Immunol; 2019; 10():2936. PubMed ID: 31921188
[TBL] [Abstract][Full Text] [Related]
17. SPARC, FOXP3, CD8 and CD45 correlation with disease recurrence and long-term disease-free survival in colorectal cancer.
Chew A; Salama P; Robbshaw A; Klopcic B; Zeps N; Platell C; Lawrance IC
PLoS One; 2011; 6(7):e22047. PubMed ID: 21818290
[TBL] [Abstract][Full Text] [Related]
18. Accumulation of FoxP3+ T regulatory cells in the tumor microenvironment of human colorectal adenomas.
Hua W; Yuan A; Zheng W; Li C; Cui J; Pang Z; Zhang L; Li Z; Goll R; Cui G
Pathol Res Pract; 2016 Feb; 212(2):106-12. PubMed ID: 26724144
[TBL] [Abstract][Full Text] [Related]
19. Co-administration of 5FU and propolis on AOM/DSS induced colorectal cancer in BALB-c mice.
Sameni HR; Yosefi S; Alipour M; Pakdel A; Torabizadeh N; Semnani V; Bandegi AR
Life Sci; 2021 Jul; 276():119390. PubMed ID: 33794252
[TBL] [Abstract][Full Text] [Related]
20. High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients.
Frey DM; Droeser RA; Viehl CT; Zlobec I; Lugli A; Zingg U; Oertli D; Kettelhack C; Terracciano L; Tornillo L
Int J Cancer; 2010 Jun; 126(11):2635-43. PubMed ID: 19856313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
